52147-97-4

Usage

Uses

Used in Pharmaceutical Industry:
BETA-STYRENE SULFONYL CHLORIDE is used as a key intermediate for the synthesis of various pharmaceuticals. Its high reactivity allows for the creation of a wide range of drug molecules, contributing to the development of new treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, BETA-STYRENE SULFONYL CHLORIDE is utilized as a crucial component in the production of various agrochemicals. Its role in this industry is vital for the development of effective pesticides and other agricultural chemicals that protect crops and enhance yields.
Used in Specialty Chemicals Synthesis:
BETA-STYRENE SULFONYL CHLORIDE is used as a versatile building block in the synthesis of specialty chemicals. Its ability to participate in multiple chemical reactions makes it an essential component in creating unique and complex chemical structures.
Used in Dye Production:
In the dye industry, BETA-STYRENE SULFONYL CHLORIDE is used as a starting material for the production of various dyes. Its chemical properties enable the creation of a broad spectrum of colors and hues for use in textiles, printing, and other applications.
Used in Organic Compounds Synthesis:
BETA-STYRENE SULFONYL CHLORIDE is employed as a reactive intermediate in the synthesis of organic compounds. Its participation in organic synthesis allows for the development of new compounds with potential applications in various industries.
Safety Note:
It is important to handle BETA-STYRENE SULFONYL CHLORIDE with caution due to its potential harmful effects if ingested, inhaled, or comes into contact with the skin or eyes. Proper safety measures should be taken during its use to ensure the well-being of individuals and the environment.

Upstream product

• 100-42-5 styrene 
• 98-85-1 1-Phenylethanol 
• 14554-08-6 ethyl (E)-2-phenylethenesulfonate 

Downstream Products

• 73300-78-4 2-Phenylvinylsulfonsaeure-methylester 
• 16212-06-9 phenyl styryl sulfone 
• 1674-29-9 (1,2,2-trichloro-ethyl)-benzene 
• 15436-11-0 (E)-methyl styryl sulfone 
• 16212-08-1 1-methyl-4-[(E)-2-phenylethenesulfonyl]benzene 
• 64984-09-4 (E)-(2-phenylethenyl)sulfonamide 
• 13719-47-6 (E)-N,2-diphenylethene-1-sulfonamide 
• 4363-40-0 2t-phenyl-ethenesulfinic acid 
• 405-18-5 trans-2-phenylethene-1-sulfonyl fluoride 
• 52148-01-3 2-nitro-trans-styrene-sulfonyl chloride-(β) 
• 52148-00-2 trans-2-(p-nitrophenyl)ethenesulfonyl chloride 
• 17299-32-0 (E)-4-<(2-phenylethynyl)sulfonyl>morpholine 
• 110417-47-5 1-Methyl-4-((E)-2-phenyl-ethenesulfonyl)-piperazine 
• 886-65-7 trans,trans-1,4-Diphenyl-1,3-butadiene 

Relevant academic research and scientific papers

Highly efficient azido-Ugi multicomponent reactions for the synthesis of bioactive tetrazoles bearing sulfonamide scaffolds

Recent studies revealed that the contribution of the different bioactive scaffolds in one structure creates modern drugs/compounds with unique synergistic biological properties. In this regard, thanks to the interesting biological and medicinal properties

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.

Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator

The main pathway responsible for cellular regulation against oxidative stress is nuclear factor E2-related factor-2 (Nrf2) signaling. We previously synthesized and reported a novel vinyl sulfone (1) as an Nrf2 activator with therapeutic potential for Parkinson's disease (PD). In this study, we changed the vinyl sulfone to vinyl sulfonamide or vinyl sulfonate to improve Nrf2 activating efficacy. We observed that the introduction of vinyl sulfonamide led to a reduction of the effects on Nrf2 activation, whereas vinyl sulfonate compounds exhibited superior activity compared to the vinyl sulfone compounds. Among the vinyl sulfonates, 3c exhibited 6.9- and 83.5-fold higher effects on Nrf2 activation than the corresponding vinyl sulfone (1) and vinyl sulfonamide (2c), respectively. Compound 3c was confirmed to induce expression of the Nrf2-dependent antioxidant enzymes at the protein level in cells. In addition, 3c mitigated PD-associated behavioral deficits by protecting DAergic neurons in the MPTP-induced mouse model of PD.

NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES

The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for

Green approach for the synthesis of thiophenyl pyrazoles and isoxazoles by adopting 1,3-dipolar cycloaddition methodology and their antimicrobial activity

A variety of N-((1,3-diphenyl-5-aryl-1H-pyrazol-4-yl)sulfonyl)thiophene-2-carboxamides (7) and N-((5-aryl-3-phenylisoxazol-4-yl)sulfonyl)thiophene-2-carboxamides (8) were prepared from (E)-N-(arylethenesulfonyl)thiophene-2-carboxamides (4) adopting 1,3-di

Desulfonylation-Initiated Distal Alkenyl Migration in Copper-Catalyzed Alkenylation of Unactivated Alkenes

A novel and efficient protocol for desulfonylation-initiated distal alkenyl migration and its application to the elusive alkenylation of unactivated alkenes have been presented. This radical cascade process has successfully achieved the vicinal difluoroal

EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Diastereoselective synthesis of novel tetra-and pentacyclic annulated coumarino-δ-sultam pyrrolidine, pyrrolizidine, pyrrolothiazole and isoxazolidine derivatives: Via intramolecular 1,3-dipolar cycloadditions

A facile and efficient strategy towards the novel tetra- and pentacyclic annulated coumarino-δ-sultam pyrrolidine, pyrrolizidine, pyrrolothiazole and isoxazolidine via intramolecular 1,3-dipolar cycloadditions of nitrones or azomethine ylides is described

Solvent-free synthesis of novel styrenesulfonamide derivatives and evaluation of their antibacterial activity

Novel N-aryl-styrenesulfonamide derivatives have been prepared from styrenesulfonyl chloride and a variety of amines under solvent-free conditions and their in vitro anti-bacterial activities against Staphylococcus aureus and Escherichia coli have been de

Design, synthesis, and biological evaluation of (E)-N-Aryl-2- arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents

A series of novel (E)-N-aryl-2-arylethenesulfonamides (6) were synthesized and evaluated for their anticancer activity. Some of the compounds in this series showed potent cytotoxicity against a wide spectrum of cancer cell-lines (IC50 values ranging from 5 to 10 nM) including all drug resistant cell-lines. Nude mice xenograft assays with compound (E)-N-(3-amino-4- methoxyphenyl)-2-(2′,4′,6′-trimethoxyphenyl)ethenesulfonamide (6t) showed dramatic reduction in tumor size, indicating their in vivo potential as anticancer agents. A preliminary drug development study with compound 6t is predicted to have increased blood-brain barrier permeability relative to many clinically used antimitotic agents. Mechanistic studies indicate that 6t and some other analogues disrupted microtubule formation, formation of mitotic spindles, and arrest of cells in mitotic phase. Compound 6t inhibited purified tubulin polymerization in vitro and in vivo and circumvented drug resistance mediated by P-glycoprotein. Compound 6t specifically competed with colchicine binding to tubulin and with similar avidity as podophylltoxin, indicating its binding site on tubulin.